MX2021008760A - Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. - Google Patents

Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2021008760A
MX2021008760A MX2021008760A MX2021008760A MX2021008760A MX 2021008760 A MX2021008760 A MX 2021008760A MX 2021008760 A MX2021008760 A MX 2021008760A MX 2021008760 A MX2021008760 A MX 2021008760A MX 2021008760 A MX2021008760 A MX 2021008760A
Authority
MX
Mexico
Prior art keywords
cd79b antibody
antigen
binding fragment
pharmaceutical use
antibody
Prior art date
Application number
MX2021008760A
Other languages
English (en)
Inventor
Cuiqing Yang
Renhong Tang
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2021008760A publication Critical patent/MX2021008760A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Microscoopes, Condenser (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-CD79B, un fragmento de unión a antígeno del mismo y su uso farmacéutico. Además, la presente invención se refiere a un anticuerpo quimérico y un anticuerpo humanizado que comprende una región CDR del anticuerpo anti-CD79B, una composición farmacéutica que comprende el anticuerpo anti-CD79B o su fragmento de unión al antígeno, y su uso como anti-CD79B. medicamento contra el cáncer. En particular, la presente invención se refiere a un anticuerpo anti-CD79B humanizado y su uso en la preparación de un fármaco para el tratamiento del linfoma (tal como DLBCL).
MX2021008760A 2019-01-28 2020-01-22 Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. MX2021008760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910083330 2019-01-28
PCT/CN2020/073803 WO2020156439A1 (zh) 2019-01-28 2020-01-22 抗cd79b抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2021008760A true MX2021008760A (es) 2021-08-24

Family

ID=71840268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008760A MX2021008760A (es) 2019-01-28 2020-01-22 Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Country Status (11)

Country Link
US (1) US20220162304A1 (es)
EP (1) EP3919516A4 (es)
JP (1) JP2022518062A (es)
KR (1) KR20210121102A (es)
CN (1) CN113286823B (es)
AU (1) AU2020213565A1 (es)
BR (1) BR112021014420A2 (es)
CA (1) CA3127556A1 (es)
MX (1) MX2021008760A (es)
TW (1) TW202031686A (es)
WO (1) WO2020156439A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214306A (zh) 2020-07-27 2022-04-16 大陸商上海拓界生物醫藥科技有限公司 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
WO2023143347A1 (zh) * 2022-01-26 2023-08-03 上海迈晋生物医药科技有限公司 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
WO2009012256A1 (en) * 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
IL287292B (en) * 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
MX2015000359A (es) 2012-07-09 2015-04-14 Genentech Inc Anticuerpos e inmunoconjugados anti-cd79b.
ES2661572T3 (es) 2012-07-09 2018-04-02 Genentech, Inc. Inmunoconjugados que comprenden anticuerpos anti-CD79b
JP6306154B2 (ja) 2013-05-02 2018-04-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アフコシル化ＣＤ２０抗体とＣＤ７９ｂ抗体−薬物コンジュゲートの併用療法
ES2886443T3 (es) 2014-08-06 2021-12-20 Astellas Pharma Inc Nuevo anticuerpo anti-Ig(beta) humana
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3227336B1 (en) 2014-12-05 2019-07-03 F.Hoffmann-La Roche Ag Anti-cd79b antibodies and methods of use
JP6793134B2 (ja) * 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
EP3307780A1 (en) 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用

Also Published As

Publication number Publication date
WO2020156439A1 (zh) 2020-08-06
BR112021014420A2 (pt) 2021-09-21
EP3919516A4 (en) 2022-11-30
TW202031686A (zh) 2020-09-01
CA3127556A1 (en) 2020-08-06
AU2020213565A1 (en) 2021-08-05
JP2022518062A (ja) 2022-03-11
CN113286823A (zh) 2021-08-20
EP3919516A1 (en) 2021-12-08
CN113286823B (zh) 2024-05-07
US20220162304A1 (en) 2022-05-26
KR20210121102A (ko) 2021-10-07

Similar Documents

Publication Publication Date Title
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
PH12016501120A1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020002406A (es) Anticuerpo anti-epha4.
EA202091747A1 (ru) Составы антитела b7-h4
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2017012615A (es) Anticuerpo anti-notch4 humano.
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.